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Abstract
Background: Healthy life expectancy – sometimes called health-adjusted life expectancy (HALE) – is a
form of health expectancy indicator that extends measures of life expectancy to account for the
distribution of health states in the population. The World Health Organization has estimated healthy life
expectancy for 192 WHO Member States using information from health interview surveys and from the
Global Burden of Disease Study. The latter estimates loss of health by cause, age and sex for populations.
Summation of prevalent years lived with disability (PYLD) across all causes would result in overestimation
of the severity of the population average health state because of comorbidity between conditions. Earlier
HALE calculations made adjustments for independent comorbidity in adding PYLD across causes. This
paper presents a method for adjusting for dependent comorbidity using available empirical data.
Methods:  Data from five large national health surveys were analysed by age and sex to estimate
"dependent comorbidity" factors for pairs of conditions. These factors were defined as the ratio of the
prevalence of people with both conditions to the product of the two total prevalences for each of the
conditions. The resulting dependent comorbidity factors were used for all Member States to adjust for
dependent comorbidity in summation of PYLD across all causes and in the calculation of HALE. A
sensitivity analysis was also carried out for order effects in the proposed calculation method.
Results: There was surprising consistency in the dependent comorbidity factors across the five surveys.
The improved estimation of dependent comorbidity resulted in reductions in total PYLD per capita ranging
from a few per cent in younger adult ages to around 8% in the oldest age group (80 years and over) in
developed countries and up to 15% in the oldest age group in the least developed countries. The effect of
the dependent comorbidity adjustment on estimated healthy life expectancies is small for some regions
(high income countries, Eastern Europe, Western Pacific) and ranges from an increase of 0.5 to 1.5 years
for countries in Latin America, South East Asia and Sub-Saharan Africa.
Conclusion:  The available evidence suggests that dependent comorbidity is important, and that
adjustment for it makes a significant difference to resulting HALE estimates for some regions of the world.
Given the data limitations, we recommend a normative adjustment based on the available evidence, and
applied consistently across all countries.
Published: 18 April 2006
Population Health Metrics 2006, 4:4 doi:10.1186/1478-7954-4-4
Received: 28 September 2005
Accepted: 18 April 2006
This article is available from: http://www.pophealthmetrics.com/content/4/1/4
© 2006 Mathers et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
Page 2 of 12
(page number not for citation purposes)
Introduction
Healthy life expectancy or health-adjusted life expectancy
(HALE) is a form of health expectancy indicator which
summarizes total life expectancy in terms of equivalent
years of full health by taking into account the prevalence
and severity distributions of health states in the popula-
t i o n  [ 1 ] .  I n  t h e  World Health Report 2000, the World
Health Organization (WHO) reported for the first time on
the average levels of population health for its 191 member
countries using HALE [2,3].
Healthy life expectancy has previously been calculated for
Australia, Canada and the United States using population
survey data on disability [4-8]. Burden of disease analyses
have also been used to calculate healthy life expectancy at
global, regional and national levels [9,10]. In the burden
of disease approach, the incidence, prevalence, duration
and severity of disabling sequelae of diseases and injuries
are estimated cause by cause for the population, for a
comprehensive set of causes. The WHO estimates of HALE
for Member States have been based on methods that com-
bine available information from health interview surveys
and from the Global Burden of Disease 2000 (GBD 2000)
study [11,12].
Use of the Global Burden of Disease estimates of health
state prevalences requires that these be added up across
disease and injury causes. However, many people have
more than one disease or injury, particularly at older ages.
This comorbidity must be taken into account in adding up
disease specific estimates if we are not to overestimate the
average loss of health in the population. Additionally, the
severity of health states associated with pairs of condi-
tions, as measured by disability weights in the GBD 2000,
may not simply be the sum of the two disability weights
for the conditions. Its likely in many cases to be less than
the sum, but in some cases there may be exacerbating
effects on health states of having both diseases.
When HALE estimates were first published in the World
Health Report 2000, adjustments were made for inde-
pendent comorbidity as described below. The methods
used were peer-reviewed during 2001 and 2002 by a Sci-
entific Peer Review Group [13] which made a number of
technical recommendations addressed in subsequent
HALE calculations. In particular, methods were developed
to take into account residents in health institutions and
dependent comorbidity.
This paper describes the approach for dealing with
dependent comorbidity. Dependent comorbidity refers to
the situation where the probability of having a pair of dis-
eases is greater than the product of the probabilities for
each disease, reflecting common causal pathways (for
example common risk factors causing both diabetes and
heart disease) and also that one disease may increase the
risk of another. The paper first presents a theoretical
approach to adjusting for dependent comorbidity, then
an operationalization of this approach using analysis of
available empirical data, and finally presents sensitivity
analyses for certain assumptions required by the method.
Previous approaches for dealing with comorbidity
Barendregt and Bonneux have carried out a sensitivity
analysis of health adjusted life expectancy to comorbidity
between five diseases (ischaemic heart disease, congestive
heart failure, cerebrovascular disease, lung cancer and
chronic obstructive pulmonary disease). They assumed
independent comorbidity: the probability of having two
diseases is the product of the probability or prevalence of
each [14]. Through a sensitivity analysis, they concluded
that the overall effect of comorbidity on estimated healthy
life expectancy is small, and that simple assumptions on
comorbidity disability weights will be acceptable, because
the impact on HALE estimates will be minor.
For the first HALE calculations reported in the World
Health Report 2000, all comorbidity between disease and
injury causes was also assumed to be independent comor-
bidity [3]. Independent comorbidity is the situation
where the probability of having two (comorbid) condi-
tions is assumed to equal the product of the probabilities
for having each of the diseases:
P1+2 = P1+P2 = 1(1-P1)× (1-P2)   (1)
where p1+2 is the prevalence of the two comorbid diseases
1 and 2, p1 is the prevalence of disease 1 and p2 the preva-
lence of disease 2. Independent comorbidity is illustrated
in Figure 1.
Independent comorbidity Figure 1
Independent comorbidity.
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The proportion of years lived at each age in equivalent
good health, required for the calculation of HALE (see
Methods section) is estimated in the burden of disease
approach using the prevalence YLD per capita for each
cause:
PYLDi = DWi× pi   (2)
where PYLDi is the prevalence YLD for cause i, DWi is the
disability weight for cause i, and pi is the prevalence rate
per capita for cause i. Ignoring comorbidity for the
moment, the total PYLD per capita summed across all
causes represents the average lost years of equivalent full
health per capita (at a given age) and one minus this
quantity represents the proportion of years lived at that
age in equivalent good health.
The simplest approach to estimating the disability weight
for the combined conditions 1 and 2 is to assume that the
health state valuations (1-disability weight) are multipli-
cative, so that the combined weight is more severe than
the weight for either condition on its own, and remains
bounded by 0 and 1 [10]. If the disability weight for the
combined conditions 1 and 2 is given by:
DW1+2 = 1-(1-DW1) × (1-DW2)   (3)
then the two calculations given by equations (1) and (3)
can be combined into a single calculation for the com-
bined prevalence YLD as follows:
PDLD1+2 = 1-(1-PYLD1) × (1-PYLD2)   (4)
This formula can be generalized to deal with more than
two causes as follows:
where Π denotes the product operator.
Adjusting for dependent comorbidity
For the second round of HALE estimates published in the
World Health Reports 2001 [15], dependent comorbidity
was explicitly taken into account for Vitamin A deficiency
and iron-deficiency anaemia (50% and 25% respectively
assumed to be comorbid with protein-energy malnutri-
tion), for diabetes with cardiovascular disease, and for
chronic obstructive pulmonary disease with cardiovascu-
lar disease (comorbidity estimated from smoking preva-
lence data as common cause) [12].
Following the scientific peer review [13], we developed a
more general and comprehensive approach to dealing
with dependent comorbidity, as described in this paper.
The approach outlined above for adjusting the sum of
PYLD for independent comorbidity can be generalized to
allow for dependent comorbidity. Let us define the
comorbidity factor f for two conditions as follows (see Fig-
ure 2):
Thus an f factor of 2 would indicate that the prevalence of
conditions 1 and 2 together is twice as common as would
be expected if the occurrence of the two conditions was
independent. An f  factor of 1 would indicate that the
comorbidity is independent. Using this f factor, and the
same assumption as above about the disability weight for
the combined conditions, we can calculate the PYLD for
conditions 1 and 2 as follows:
PYLD1+2 = PYLD1+PYLD2 - f1+2 × PYLD1 × PYLD2
= PYLD1 + (1-f1+2 × PYLD1) × PYLD2   (7)
where f1+2 denotes the f factor for the two conditions 1 and
2.
When there are more than 2 causes, calculation of the
total PYLD for all causes using the above approach would
involve all pairwise f  factors plus potential terms for
higher order comorbidity between 3 or more conditions.
This complexity can be avoided by taking a sequential
approach to the calculation of the total PYLD, where at
each step the PYLD for condition j+1 is added to the total
PYLD for conditions 1 to j, and the required f factor is that
for condition j with the total prevalence for conditions 1
to j:
PYLD PYLD total i
i
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f
p
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12
12
6 +
× ()
Dependent comorbidity Figure 2
Dependent comorbidity.
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PYLD1+...+(j+1) = PYLD1+...+j + (1-f(1+...+j)+(j+1) × PYLD1+...+j) ×
PYLDj+1   (8)
Methods
Analysis of dependent comorbidity reported in national 
health surveys
Data from five large national health surveys in Australia,
United States of America, Denmark and Belgium (see
Table 1) were analysed by age and sex to estimate
"dependent comorbidity" f factors for pairs of conditions.
These conditions were self-reported by survey respond-
ents. To enable results for f factors to be compared and
pooled across surveys, it was necessary to group self-
reported conditions into broad disease and injury catego-
ries to avoid problems arising from differences in finer
disease labels used. It was also decided that too many dis-
ease categories would be inappropriate given sample sizes
and the low prevalences of many specific conditions. The
final set of categories used were cardiovascular conditions
and diabetes, chronic respiratory conditions, muscu-
loskeletal conditions, nervous system conditions, mental
disorders, and other conditions (including infectious dis-
eases and injuries and their sequelae).
The Australian National Health Survey 1995 [16] was con-
ducted on a multistage, cluster sample of households in
all states and territories of Australia. Information was
obtained by personal interviews of 53,751 persons. The
survey contains detailed information on health status,
including self-reports of recent and long-term medical
conditions experienced by respondents. The Australian
National Survey of Mental Health and Wellbeing 1997
[17,18] provided information from personal interviews of
10,600 persons aged 18 years or more on the prevalence
of selected major mental disorders, and on chronic phys-
ical conditions and disability. The response rate was 78%.
The US National Health Interview Survey 2000 [19] col-
lected self-reported information on health status and ill-
ness conditions. We utilized information from
respondents 18 years and older. The response rate was
82.6% and the adult sample size was 32,374 persons.
The Danish Health and Morbidity Survey 1994 [20,21]
contains information from 4,668 persons obtained from
a representative national sample plus 2,119 persons from
two Danish counties collected in the same year, resulting
in a total sample of 6,787 adult persons over 16 years of
age. The overall response rate to the interviews was 79%.
Data were collected through a 45 minute interview
together with a self-administered questionnaire to be
mailed back within two weeks.
The Belgian Health Interview Survey 1997 [22] consisted
of three parts: 1) a household survey for household and
demographic information, 2) a self-administrated ques-
tionnaire including questions on health complaints and
symptoms, and mental health, and 3) a face-to-face inter-
view including questions on chronic diseases, limitations
and handicaps. The survey was of 7,967 persons 15 years
and older in Belgium's three regions the Flemish Region,
the Walloon Region and the Brussels Region. The overall
response rate was 60.5%.
Adjustment of HALE for dependent comorbidity
HALE estimates for WHO Member States have been car-
ried out using Sullivan's method [23], which requires
three inputs: life tables and prevalences of various states of
health together with appropriate severity weights. The
development of WHO life tables and of health state sever-
ity weights is described elsewhere [11,24,25], we focus
here on the estimation of health state prevalences.
The health state valuations used in HALE calculations rep-
resent average population assessments of the overall
health levels associated with different states. They range
from 1 representing a state of good or ideal health to 0
representing states equivalent to being dead. Sullivan's
method requires estimates of age- and sex-specific average
health state valuations for the population for the specified
time period (usually a calendar year). We use the notation
Hx,s to denote the population average health state valua-
tion for sex s and age group x. If Lx,s represents the total life
table years lived by sex s in the age range corresponding to
x, then HALEa,s at exact age a is calculated by summing the
Table 1: Five population health surveys used in analysis. Year of survey, sample size, and abbreviation used in other tables.
Abbreviation Survey Year Sample size
AUSNHS Australian National Health Survey 1995 53,700
AUS NMHS Australian National Survey of Mental Health and Wellbeing 1997 10,600
US NHIS US National Health Interview Survey 2000 32,375
Denmark Danish Health and Morbidity Survey 1994 6,786
Belgium Belgian Health Interview Survey 1997 7,967Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
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healthy years of life lived for each age group from a
onwards and dividing by the number of life table survi-
vors la,s at exact age a:
In calculating HALE for the World Health Report 2000,
WHO carried out an analysis of 62 representative popula-
tion health surveys which revealed substantial problems
with comparability of self-report health status and disabil-
ity data [3]. As a result disability prevalence estimates
from the GBD 2000 were used to adjust for biases in self-
report data; the independent information on levels of
population health provided by the health surveys was
thus quite limited.
WHO undertook a Multi-Country Survey Study on Health
and Responsiveness (MCSS) in 2000 and 2001 in collab-
oration with Member States using a standardized health
status survey instrument together with new statistical
methods for to adjust for biases in self-reported health
[26-29]. These new data, together with comprehensive
analyses of epidemiological data for all regions of the
world from the GBD 2000, were used to calculate healthy
life expectancy for WHO Member States for 2002 using
methods explicitly developed to maximise comparability
across countries. These methods are summarized below
and described in more detail elsewhere [11,12].
Because the MCSS surveys were carried out in only 61
Member States, a three-stage strategy was used to obtain
comparable health state prevalences for all 192 Member
States. Firstly, data from the MCSS were used to make
independent estimates of Hx,s by age and sex for 58 coun-
tries (three were excluded due to survey quality issues).
The MCSS survey samples did not include older people
resident in nursing homes or other health institutions.
Because these people will generally have worse health
than those resident in households, adjustments were
made to the Hx,s estimates to account for the older popu-
lation who were resident in health institutions [11].
Secondly, data from the GBD 2000 were used to estimate
Hx,s by age and sex for all 192 countries for the year 2002.
The GBD estimated years lived with disability (YLD) for
135 major causes, for 17 sub-regions of the world [30].
The GBD analyses were used to prepare estimates of mor-
tality and burden of disease for each WHO Member States
for the year 2002. Mortality estimates were based on anal-
ysis of latest available national information on levels of
mortality and cause distributions. YLD estimates were
based on the GBD analyses of incidence, prevalence, dura-
tion and severity of conditions for the relevant epidemio-
logical subregion, together with national and subnational
level information available to WHO [31].
As well as the standard incidence-based YLD, prevalence-
based YLD rates were calculated for each cause, as given by
equation (2). For the original HALE estimates published
in 2000 and 2001, the prevalence YLD were added across
causes with adjustment for independent comorbidity as
given by equation (5). For the later estimates published in
World Health Reports in 2003 and 2004 [32,33], adjust-
ments for dependent comorbidity were carried out using f
factors from analysis of the five surveys described above.
The f factors from the survey analyses were compared and
averaged to give a final set of dependent comorbidity fac-
tors used for adjusting the summation of PYLD across
causes for each country. The adjustments were carried out
using the cumulative method outlined above and the fol-
lowing sequence of cause groups: cardiovascular disease
and diabetes, chronic respiratory diseases, musculoskele-
tal diseases, sight or hearing loss, Group 1 conditions
(communicable, maternal, perinatal and nutritional con-
ditions), injuries, other diseases, neurological diseases,
mental disorders.
For all WHO HALE calculations irrespective of method of
comorbidity adjustment, the final prevalence YLD rate per
capita summed across all causes was used to estimate aver-
age "prior" health state valuations for the populations of
WHO Member States:
Because there is potential measurement error in severity-
weighted health state prevalences derived from both
household surveys and epidemiological estimates, poste-
rior estimates of prevalence for the survey countries were
calculated as weighted averages of the GBD-based preva-
lences and the survey prevalences:
where the weights wx,s were based on the estimated relative
uncertainties of the GBD and survey-based population
average health state valuations Hx,s for sex s and age group
x. The relationship between the GBD-based   and
the posterior   was estimated for the survey coun-
tries using ordinary least squares regression and the results
used to adjust the   for the non-survey countries.
This ensured that the use of the survey data did not intro-
HALE H L l as xs xs
xa
as ,, , , =− ()


 


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≥
∑ 19
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duce a differential between survey and non-survey coun-
tries, and allowed the survey evidence to be indirectly
taken into account in making the best possible estimates
for non-survey countries.
Sensitivity analyses
A sensitivity analysis was carried out of the impact of the
magnitude of the f factor on the adjustment to total PYLD
and hence to estimates of Hx,s. For this analysis, the f fac-
tors were assumed to be the same across all sequential
condition groups and varied from 1 (independent comor-
bidity) through to 5.
As noted above, self-reported conditions were grouped
into broad disease and injury categories for the analysis of
f factors from the survey data. A second sensitivity analysis
was carried out to examine the sensitivity of the HALE esti-
mates to the sequencing of the disease and injury groups
for the dependent comorbidity adjustments.
Results
Table 2 shows the f factors calculated from the five survey
datasets. Differences in the comprehensiveness in self-
reported conditions collected in the various surveys
meant that f factors for some categories could not be cal-
culated for some of the surveys. However they have been
included in the table for comparison. There was surprising
consistency in the f factors across the five surveys, both in
terms of the magnitudes and the age patterns. The f factors
were typically around 1.5 to 2 at older ages, around 3 to 5
at middle ages and higher at younger ages (where preva-
lences are typically low). An f factor of 5 at middle ages
signifies that the prevalence of the comorbid pair of con-
ditions is five times higher than would be expected by
chance alone based on the observed prevalences for each
of the conditions considered separately,
A final set of f factors were calculated by averaging the f
factors across surveys and applying these f factors to a
slightly more detailed set of sequential cause categories.
The dependent comorbidity factors shown in Table 3 were
used for all Member States to adjust for dependent comor-
bidity in summation of prevalence YLD across all causes,
as there was insufficient evidence to justify use of different
f factors in different regions of the world.
Figure 4 shows the results for males aged 80 years and over
for a typical developing country. Simple addition of PYLD
Table 2: Comorbidity factors from five population surveys. Comorbidity factors for cumulative cause groups by age and sex. The 
comorbidity factor f is computed using equation (6) as the prevalence of persons reporting diseases in the two cause groups (p1+2) 
divided by the two prevalences p1 and p2 for each cause group considered independently: f = p1+2/(p1 × p2)
Males Females
Survey Combinations < 30 30–44 45–59 60 –74 75+ < 30 30–44 45–59 60–74 75+
AUSNHS Cardiovascular + respiratory 114.77 43.84 7.93 4.05 7.36 48.36 16.14 9.72 6.03 6.80
Previous + musculoskeletal 5.91 8.73 5.12 2.84 4.27 5.77 5.68 4.89 3.84 4.31
Previous + other 3.87 2.58 1.72 1.40 1.72 3.87 2.64 1.78 1.38 1.65
Previous + nervous 4.88 3.47 2.25 1.64 2.13 4.72 3.28 1.94 1.47 1.92
Previous + mental 2.93 2.01 1.43 1.20 1.45 2.87 1.98 1.47 1.25 1.43
AUS NMHS Cardiovascular + respiratory -- -- 9.66 3.76 4.05 41.99 35.78 14.62 6.12 4.53
Previous + musculoskeletal 37.19 33.12 8.47 3.47 3.52 27.62 21.66 11.54 5.13 4.21
Previous + other 23.44 15.85 4.03 2.07 2.21 19.34 10.31 3.56 1.91 1.89
Previous + mental 4.76 4.83 2.29 1.44 1.73 4.25 3.93 2.09 1.37 1.46
US NHIS Cardiovascular + respiratory 9.97 4.10 1.80 2.59 1.77 8.14 4.12 2.20 1.42 2.37
Previous + musculoskeletal 7.07 3.55 1.64 2.38 1.56 4.78 3.07 1.89 1.31 2.24
Previous + other 2.00 2.00 1.56 1.22 1.22 1.92 1.92 1.57 1.27 1.27
Previous + mental 1.84 1.84 1.46 1.15 1.15 1.65 1.65 1.39 1.17 1.17
Denmark Cardiovascular + respiratory 32.71 32.71 14.05 6.04 6.04 41.56 41.56 15.63 5.87 5.87
Previous + musculoskeletal 13.49 13.49 5.76 2.46 2.46 14.38 14.38 7.43 3.84 3.84
Previous + other 4.15 4.15 2.61 1.64 1.64 4.35 4.35 2.66 1.63 1.63
Previous + nervous 4.08 4.08 2.63 1.69 1.69 4.46 4.46 2.73 1.67 1.67
Previous + mental 3.12 3.12 2.09 1.40 1.40 3.20 3.20 2.05 1.32 1.32
Belgium Cardiovascular + respiratory 33.02 33.02 11.66 4.12 4.12 43.21 43.21 15.74 5.73 5.73
Previous + musculoskeletal 11.06 11.06 5.28 2.52 2.52 11.12 11.12 6.31 3.58 3.58
Previous + mental 5.90 5.90 3.27 1.81 1.81 5.72 5.72 3.48 2.12 2.12Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
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across causes without any adjustment for comorbidity
results in a total PYLD of 0.85 (an average health state
equivalent to severe Alzheimer's disease or quadriplegia).
Adjustment for independent comorbidity (f = 1) reduces
this to around 0.59, still a health state more severe than
blindness. As the f factor increases up to 5, the average
health state valuation reduces to around 0.33, not as
severe but still a state of considerable health problems.
The overall effect of the introduction of the dependent
comorbidity adjustment is a reduction across all countries
in the total PYLD rate per capita by age and sex from the
GBD 2000 country estimates, and hence an increase in
healthy life expectancy. The amount of change varies
somewhat across regions. The improved estimation of
dependent comorbidity resulted in reductions in total
PYLD per capita ranging from a few per cent in younger
adult ages to around 8% in the oldest age group (80 years
and over) in developed countries and up to 15% in the
oldest age group in the least developed countries.
Figure 4 illustrates the impact of the dependent comorbid-
ity adjustment on regional healthy life expectancy at birth
in 2002. The bars labelled 2002 were calculated using the
2002 country life tables, the health state valuations from
the MCSS surveys and the Global Burden of Disease esti-
mated PYLD for 2002 with dependent comorbidity
adjustments. The bars labelled 2001 show the same
healthy life expectancies calculated with the Global Bur-
den of Disease inputs replaced by estimated PYLD for
2001 with independent comorbidity adjustments. The
differences are slight for low mortality countries, Eastern
Europe, China and the Western Pacific. In contrast, the
dependent comorbidity adjustments increase healthy life
expectancy by around 0.5 to 1.5 years for Latin America,
South East Asia and Sub-Saharan Africa.
The analysis of the surveys was repeated to calculate f fac-
tors for sequentially cumulative cause groups using three
different orderings of the cause groups, in order to test the
sensitivity of the results to the assumed order. The three
orders are shown in Table 4.
The age standardized PYLD rate per capita (a number
between 0 and 1 corresponding to the average health state
valuation H) is shown in Table 5 for the three orderings
for a developing country (Ghana) and a developed coun-
try (Sweden). Dependent comorbidity adjustment of any
Table 4: Three orderings of cumulative condition groups for sensitivity analysis. Three orderings of cumulative condition groups for 
analysis of dependent comorbidity factors and sensitivity of dependent comorbidity adjustments to condition ordering.
O r d e r  1O r d e r  2O r d e r  3
Cardiovascular + respiratory Musculoskeletal + nervous system Mental + respiratory
Previous + musculoskeletal Previous + Cardiovascular Previous + musculoskeletal
Previous + injuries Previous + respiratory Previous + Cardiovascular
Prev + nervous system Previous + Group 1 Prev + nervous system
Previous + Group 1 Previous + other Previous + Group 1
Previous + other Previous + mental Previous + other
Previous + mental Previous + injuries Previous + injuries
Table 3: Final dependent comorbidity factors. Dependent comorbidity factors f used in the calculation of all-cause PYLD per capita. 
The comorbidity factor f is defined as the prevalence of persons with comorbid diseases in the two cause groups divided by the two 
prevalences for each cause group considered independently, f = p1+2/(p1 × p2).
Males Females
Condition pair 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+
CVD + diabetes 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
+ respiratory* 26.2 26.2 26.2 15.1 5.9 3.7 3.7 3.6 25.0 25.0 25.0 16.1 7.4 3.7 4.0 4.2
+ Musculoskeletal 10.9 10.9 10.9 9.0 3.9 2.7 2.6 2.5 9.1 9.1 9.1 7.6 4.6 2.8 3.0 3.3
+ Sight or hearing loss 5.2 5.2 5.2 4.3 2.3 1.6 1.6 1.7 5.0 5.0 5.0 3.9 2.3 1.5 1.6 1.6
+ Group1*** 5.2 5.2 5.2 4.3 2.3 1.6 1.6 1.7 5.0 5.0 5.0 3.9 2.3 1.5 1.6 1.6
+ Injuries 4.9 4.9 4.9 4.2 2.6 1.7 1.8 1.9 4.8 4.8 4.8 4.0 2.4 1.6 1.7 1.9
+ Other diseases 5.2 5.2 5.2 4.3 2.3 1.6 1.6 1.7 5.0 5.0 5.0 3.9 2.3 1.5 1.6 1.6
+ Neurological 4.5 4.5 4.5 3.8 2.3 1.6 1.5 1.5 4.5 4.5 4.5 3.8 2.3 1.6 1.5 1.5
+ Mental disorders 4.1 4.1 4.1 3.9 2.2 1.4 1.5 1.6 3.9 3.9 3.9 3.5 2.2 1.5 1.5 1.5
*The first condition of each pair is the cumulative prevalence of having one or more of the conditions in preceding rows.
*** Communicable diseases, maternal and perinatal conditions and nutritional deficiencies.Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
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kind makes a big difference to the total PYLD rate, there
are also some smaller differences between the results for
the three orderings. The corresponding differences in
HALE at birth are shown in the 2 right hand columns of
Table 5. Adjustment for dependent comorbidity increases
HALE by around 1 year for both males and females in
Ghana and for females in Sweden, and by around 0.5
years for males in Sweden. The ordering of the condition
groups in carrying out the adjustment makes some differ-
ence also, with a range of around 0.3 years for males in
Sweden and females in Ghana, and around 0.6 years for
males in Ghana and females in Sweden.
Discussion and conclusion
Previous HALE calculations based on condition-specific
data have made comorbidity adjustments on the assump-
tion that the probability of occurrence of different dis-
eases in one individual are statistically independent. This
paper has presented a general method for making comor-
bidity adjustments taking into account dependent comor-
bidity, that is, the situation where pairs of disease occur
with greater frequency than would be they case if they
were independent. Quantification of dependent comor-
bidity was based on an analysis of self-reported data from
five large national health surveys.
The available evidence suggests that dependent comorbid-
ity is important, and that adjustment for it makes a signif-
icant difference to resulting HALE estimates for some
regions of the world. The improved estimation of depend-
ent comorbidity resulted in reductions in total PYLD per
capita ranging from a few per cent in younger adult ages
to around 8% in the oldest age group (80 years and over)
in developed countries and up to 15% in the oldest age
group in the least developed countries. This has resulted
in an upward adjustment in the HALE estimates for WHO
Member States reflecting the consistent evidence from
health surveys that dependent comorbidity is common
for most conditions.
To date, this evidence is based on health surveys from
developed countries, and it will be important to extend
this analysis to health surveys in developing countries.
However, in extending the analysis, it will be difficult to
take into account the known differences in reporting
behaviour for illnesses and impairments between people
Table 5: Sensitivity analysis of ordering of cumulative condition groups. Sensitivity of estimated age-standardized average health state 
valuation H and of estimated HALE at birth to three orderings of cumulative condition groups for dependent comorbidity adjustments 
for a developed country and a developing country.
Age-standardized average health state valuation H HALE at birth (years)
Male Female Male Female
Ghana
Independent comorbidity 0.151 0.096 46.8 48.9
Order 1 0.134 0.089 47.8 49.9
Order 2 0.128 0.088 48.1 50.0
Order 3 0.128 0.085 48.5 50.3
Sweden
Independent comorbidity 0.066 0.044 70.5 72.6
Order 1 0.062 0.042 70.9 73.3
Order 2 0.060 0.041 71.0 73.6
Order 3 0.056 0.039 71.2 73.9
Sensitivity of average health state valuation to dependent  comorbidity factor f Figure 3
Sensitivity of average health state valuation to 
dependent comorbidity factor f. Variation of average 
health state valuation for age group 80 and over with 
assumed value of dependent comorbidity factor f (same fac-
tor assumed for all disease pairs): example for males in a 
developing country.
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in developing and developed countries [34,35]. Many sur-
veys have shown that people in developing countries
report much lower prevalences of illnesses and impair-
ments. In part this is due to lower access to health services
resulting in less awareness of illnesses, and in part to dif-
ference implicit standards for labelling and reporting
health problems. Such differences will make it difficult to
interpret whether differences in f  factors between self-
report data in developing and developed countries are real
or are a result of differences in reporting behaviours.
We have chosen to apply the f factors, derived in our anal-
ysis of five large surveys in four countries, to all countries
as a normative evidence-based adjustment for dependent
comorbidity as it seems unlikely that unbiased evidence
on differences in dependent comorbidity across countries
and regions is feasible in the near future.
The sensitivity to order of adjustment, noted above in the
sensitivity analysis, is also a result of using self-report data
from surveys for the estimation of f factors. If a consistent
set of disease prevalences were used for the estimation of
f factors and for the calculation of PYLD then the sequen-
tial cumulative adjustment method must be independent
of order (this can be shown mathematically). Because we
are using f factors derived from self-report survey data,
and applying them to GBD estimates of prevalences
derived from synthesis of epidemiological data from pop-
ulation studies using carefully defined case definitions for
diseases and their sequelae, the results may depend on the
A comparison of regional healthy life expectancy at birth in 2002 calculated with and without dependent comorbidity adjust- ment Figure 4
A comparison of regional healthy life expectancy at birth in 2002 calculated with and without dependent 
comorbidity adjustment. Healthy life expectancy (HALE) and Lost Health Expectancy (LHE) at birth in 2002, calculated 
using as inputs the GBD estimated PYLD for 2002 with dependent comorbidity adjustments (bars labelled 2002) and the GBD 
estimated PYLD for 2001 with independent comorbidity adjustments (bars labelled 2001).
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order of adjustment. This is because the GBD prevalences
are not necessarily consistent with the survey self-report
prevalences.
The only way to properly solve this problem is to carry out
a very large population survey in which prevalences are
ascertained using appropriate diagnostic tests and GBD
case definitions. This would be so expensive as to almost
certainly never be likely to be carried out. It would cer-
tainly be possible to obtain more rigorous data on
dependent comorbidity for some selected condition pairs,
for example from countries with comprehensive person-
based medical records, but this would not help us solve
the full comorbidity adjustment problem.
The order that we have chosen for the adjustment of HALE
gives an increase in HALE at the lower end of the range. In
other words, it is a more conservative adjustment than
given by the other orderings. If it is possible to obtain
analyses of f factors for condition pairs based on more
objective case definitions consistent with those used in
the GBD 2000, then it might be possible to take these into
account in adjusting for dependent comorbidity in HALE.
The analyses reported here could be used to make an ini-
tial determination of the most important condition pairs
for dependent comorbidity adjustment (this would take
into account prevalence, severity and best estimate of f fac-
tors). Such a short list of important pairs could then be
used to search for empirical evidence to improve the
adjustments for these pairs.
Another area requiring further investigation is the estima-
tion of disability weights for comorbid pairs of condi-
tions. The usual techniques for eliciting health state
valuations either present valuers with a pure health state
description (using the Euroqol or HUI or similar multi-
domain health state description tool) or with a disease
label. Sometimes the disease label is supplemented with a
health state description [36] or the respondent is asked to
write the health state description for the disease label they
are valuing (MCSS). Extending these approaches to
comorbid pairs of conditions seems to present a lot of dif-
ficulty. The respondents are either guessing what the
impact of the pair of conditions is on the health state pro-
file, or there is a need for that to be provided from empir-
ical studies.
A number of studies have examined the impact of comor-
bidity on overall levels of disability or functioning, usu-
ally for a selected small group of conditions. Although
some of these also provide information on the probability
of comorbidity for condition pairs, this has been a less
obvious focus of research relating to comorbidity.
One large study of the impact of comorbidity of common
impairments in older people on Activities of Daily Living
(ADL) and Instrumental Activities of Daily Living (IADL)
found that only a few combinations including vision and
hearing loss acted to further exacerbate the effects of other
impairments on disability [37]. A number of studies in
Mexican-Americans, Americans, Canadians and Koreans
have found that depression and comorbid medical condi-
tions interact to increase the probability of depression and
to reduce the health-related quality of life [38-44]. Certain
physical conditions have also been found to be associated
with a significantly increased likelihood of panic attacks
[45,46].
A recent Dutch study of 1,673 non-institutionalized
chronic disease patients found synergistic effects of com-
binations of diabetes, cardiovascular disease and chronic
respiratory disease with a higher risk of physical disability
than could be expected from their separate effects [47].
However, while these types of studies tell us that the disa-
bility associated with a comorbid state may be greater
than the disability associated with either condition, they
have not addressed the issue of whether the disability
weights would be additive or sub-additive, as has been
assumed in the methods outlined above. In the absence of
such studies, the multiplicative assumption used here
seems a reasonable step.
Barendregt and Bonneux concluded in their earlier paper
that ignoring comorbidity is an attractive option because
of the difficulty of bring empirical data to bear and the
complex adjustments required, and that simple assump-
tions will probably serve because the impact on HALE
estimates is minor [14]. We have shown that the available
evidence suggests that dependent comorbidity is impor-
tant, and that adjustment for it makes a significant differ-
ence to resulting HALE estimates. Given the data
limitations, a normative adjustment based on the availa-
ble evidence, but applied consistently across all countries,
seems to be the most justifiable approach. This is the
approach that has been taken for the calculation of HALE
for WHO Member States in recent World Health Reports
[32,33].
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CM conceived the approach to adjustment for dependent
comorbidity, KMI and SB carried out analyses of the five
health surveys, CM and KMI undertook sensitivity analy-
ses, calculations of healthy life expectancies and initial
drafting of the paper. All three authors contributed to the
writing of the paper.Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
Page 11 of 12
(page number not for citation purposes)
Acknowledgements
We wish to acknowledge useful discussions with Christopher JL Murray, 
Joshua Salomon and Niels Tomijima. Niels Tomijima also carried out calcu-
lations of PYLD rates for countries using the dependent comorbidity 
adjustments described in this paper.
References
1. Murray CJL, Salomon JA, Mathers CD: A critical examination of
summary measures of population health.  Bulletin of the World
Health Organization 2000, 78:981-994.
2. Organization WH: World Health Report 2000. Health Systems: Improv-
ing Performance 2000 [http://www.who.int/whr]. Geneva, WHO
3. Mathers CD, Sadana R, Salomon JA, Murray CJL, Lopez AD: Healthy
life expectancy in 191 countries, 1999.  Lancet 2001, 357:
1685-1691.
4. Wilkins R, Adams OB: Health expectancy in Canada, late
1970's: demographic, regional and social dimensions.  Ameri-
can Journal of Public Health 1983, 73:1073-1080.
5. Wolfson MC: Health-adjusted life expectancy.  Health Reports
1996, 8:41-46.
6. Mathers CD: Gains in health expectancy from the elimination
of diseases among older people.  Disability and Rehabilitation
1999, 21:211-221.
7. CDC: Years of healthy life -- selected states, United States,
1993-1995.  JAMA 1998, 279:649.
8. U.S.Department of Health and Human Services: Healthy People 2010.
With Understanding and Improving Health and Objectives for Improving
Health 2 2000 [http://www.health.gov/healthypeople]. Washington,
D.C., U.S. Government Printing Office
9. Murray CJL, Lopez AD: Regional patterns of disability-free life
expectancy and disability-adjusted life expectancy: Global
Burden of Disease Study.  Lancet 1997, 349:1347-1352.
10. Mathers CD, Vos T, Stevenson C: The burden of disease and injury in
Australia Australian Institute of Health and Welfare, Canberra, AIHW;
1999. 
11. Mathers CD, Iburg K, Salomon J, Tandon A, Chatterji S, Ustun B, Mur-
ray CJL: Global patterns of healthy life expectancy in the year
2002.  BMC Public Health 2004, 4:66.
12. Mathers CD, Murray CJL, Salomon JA: Methods for measuring
healthy life expectancy.  Health systems performance assess-
ment:debates, methods and empiricism. 2003:437-470 [http://
www.who.int/publications/2003/hspa/en/]. Geneva, World Health
Organisation
13. Anand S, Ammar W, Evans T, Hasegawa T, Kissimova-Skarbek K,
Langer A, et.al.: Report on the Scientific Peer Review Group on
Health Systems Performance Assessment.  In Health systems
performance assessment: debates, methods and empricism Edited by:
Murray CJL and Evans D. Geneva, World Health Organisation; 2003. 
14. Barendregt JJ, Bonneux L: Disability adjusted life expectancy and
comorbidity: exploring uncertainty and sensitivity.  I n
Towards an integrated system of indicators to assess the health status of
the population: 9th REVES International Meeting Proceedings Rome,
National Institute of Statistics; 1999:11-26. 
15. Organization WH: World Health Report 2002. Reducing Risks, Promoting
Healthy Life. Geneva, WHO; 2002. 
16. Statistics AB: National Health Survey: user's guide 1995.  Can-
berra, ABS; 1996. 
17. Statistics AB: National survey of mental health and wellbeing
of adults: users' guide.  Canberra, ABS; 1999. 
18. Statistics AB: Menatl health and wellbeing: profile of adults.
Canberra, ABS; 1998. 
19. Statistics NCH: Data File Documentation, National Health
Interview Survey, 2000 (machine readable data file and doc-
umentation).  Hyattsville, Maryland, National Center for Health
Statistics; 2002. 
20. Health NIP: Danish Health and Morbidity Survey 1994.  Den-
mark, National Institute of Public Health; 1994. 
21. Kjoller M, Rasmussen NK, Keiding L, Petersen HC, Nielsen GA:
Health and morbidity in Denmark 1994 - and the development since 1987
(In Danish) Copenhagen, Danish Institute for Clinical Epidemiology;
1995. 
22. Health SIP: Belgium Health Interview Survey 1997.  Center for
Operational Public Health Research, Department of Epidemiology,
Scientific Institute of Public Health; 1997. 
23. Sullivan DF: A single index of mortality and morbidity.  HSMHA
Health Reports 1971, 86:347-354.
24. Lopez AD, Ahmad O, Guillot M, Ferguson B, Salomon JA, Murray CJL,
Hill KH: World Mortality in 2000: life tables for 191 countries. Geneva,
World Health Organization; 2002. 
25. J.A. S, C.J.L M: A multi-method approach to estimating health
state valuations.  Health Economics 2004, 13:281-290.
26. Ustun TB, Chatterji S, Villanueva M, Bendib L, Celik C, Sadana R, Val-
entine N, Ortiz J, Tandon A, Saloman J, Cao Y, Xie Wan J, Ozaltin E,
Mathers CD, C.J.L M: The WHO Multicountry Household Sur-
vey Study on Health and Responsiveness 2000-2001.  I n
Health systems performance assessment: debates, methods and empiricism
Edited by: Murray CJL and Evans D. Geneva, World Health Organisa-
tion; 2003. 
27. King G, Murray CJL, Salomon JA, Tandon A: Enhancing the validity
and cross-cultural comparability of measurement in survey
research.  American Political Science Review 2003, 93:567-583.
28. Salomon JA, Tandon A, C.J.L M, World Health Survey Pilot Collabo-
rating Group: Unpacking health perceptions: multi-country
survey study using anchoring vignettes to enhance compari-
sons of self-rated health.  British Medical Journal 2004, 328:
258-261.
29. Murray CJL, Tandon A, Salomon JA, Mathers CD: New approaches
to enhance cross-population comparability of survey results
.  In Summary measures of population health: concepts, ethics, measure-
ment and applications Edited by: Murray CJL, Salomon JA, Mathers CD
and Lopez AD. Geneva, World Health Organization; 2002. 
30. Mathers CD, Bernard C, Iburg KM, Inoue M, Ma Fat D, Shibuya K,
Stein C, Tomijima N, Xu H: Global Burden of Disease in 2002:
data sources, methods and results.  Geneva, World Health
Organization; 2003. 
31. Mathers CD: Uncertainty and data availability for the Global
Burden of Disease estimates 2000-2002.  Geneva, World
Health Organization; 2005. 
32. Organization WH: World Health Report 2003: shaping the future.
Geneva, WHO; 2003. 
33. Organization WH: World Health Report 2004: Changing History.
Geneva, WHO; 2004. 
34. Murray CJL, Chen LC: Understanding morbidity change.  Popu-
lation and Development Review 1992, 18:481-503.
35. Sadana R, Mathers CD, Lopez AD, Murray CJL, Moesgaard-Iburg K:
Comparative analyses of more than 50 household surveys on
health status.  In Summary measures of population health: concepts,
ethics, measurement and applications Edited by: Murray CJL, Salomon
JA, Mathers CD and Lopez AD. Geneva, World Health Organization;
2002:369-386. 
36. Stouthard M, Essink-Bot M, Bonsel G, Barendregt J, Kramers P: Disa-
bility weights for diseases in the Netherlands Rotterdam, Department of
Public Health, Erasmus University; 1997. 
37. Kempen GI, Verbrugge LM, Merill SS, Ormel J: The impact of mul-
tiple impairments on disability in community-dwelling older
people.  Age and Ageing 1998, 27:595-604.
38. Black SA, Goodwin JS, Markides KS: The association between
chronic diseases and depressive symptomatology in older
Mexican Americans.  Journal of Gerontology 1998, 53:M188-M194.
39. Black SA: Increased health burden associated with comorbid
depression in older diabetic Mexican American. Results
from the hispanic established population for the epidemio-
logic study of the elderly survey.  Diabetes Care 1999, 22:56-64.
40. Gaynes BN, Burns BJ, Tweed DL, Erickson P: Depression and
health related quality of life.  J Nerv Ment Dis 2002, 190:799-806.
41. Mills TL: Comorbid depressive symptomatology.  Social Science
& Medicine 2001, 53:569-578.
42. Chou KL, Chi I: Chronic illness and depressive symptoms
among Chinese older adults: a longitudinal study.  Interna-
tional J Aging and Human Development 2002, 54:159-171.
43. Patten SB: Long-term medical conditions and major depres-
sion in the Canadian population.  Canadian Journal of Psychiatry -
Revue Canadienne de Psychiatrie 1999, 44:151-157.
44. Lee Y, Choi K, Lee YK: Association of comorbidity with depres-
sive symptoms in community-dwelling older persons.  Geron-
tology 2001, 47:254-262.
45. Goodwin RD, Pine DS: Respiratory disease and panic attacks
among adults in the United States.  Chest 2002, 122:645-650.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Population Health Metrics 2006, 4:4 http://www.pophealthmetrics.com/content/4/1/4
Page 12 of 12
(page number not for citation purposes)
46. Goodwin RD: Self-reported hay fever and panic attacks in the
community.  Ann Allergy Asthma Immunol 2002, 88(6):556-559:
556-559.
47. Rijken M, van Kerkhof M, Dekker J, Schellevis FG: Comorbidity of
chromic diseases: effects of disease pairs on physical and
mental functioning.  Quality of Life Research 2005, 14:45-55.